These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2716194)

  • 21. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
    Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
    Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study.
    Laporte JP; Isnard F; Lesage S; Fenaux P; Douay L; Lopez M; Stachowiak J; Najman A; Gorin NC
    Leukemia; 1993 Dec; 7(12):2030-3. PubMed ID: 8255103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
    Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
    J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
    Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
    Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Anderlini P; Luna M; Kantarjian HM; O'Brien S; Pierce S; Keating MJ; Estey EH
    Leukemia; 1996 Apr; 10(4):600-8. PubMed ID: 8618434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A phase II study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. Cooperative Study Group for PL-AC].
    Kimura K
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2475-81. PubMed ID: 3619459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study.
    Yoshida Y; Oguma S; Uchino H; Maekawa T; Nomura T
    Int J Clin Pharmacol Res; 1993; 13(1):21-7. PubMed ID: 8509233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on pathophysiology of the myelodysplastic syndromes (MDS)--pattern of dysmegakaryopoiesis related to leukemic transformation].
    Tomonaga M; Jinnai I; Kuriyama K; Nonaka H; Amenomori T; Matsuo T; Yoshida Y; Sasagawa I; Sadamori N; Ichimaru M
    Rinsho Ketsueki; 1989 Oct; 30(10):1788-99. PubMed ID: 2593245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Munshi NC; Tricot GJ
    Ann Hematol; 1997 Mar; 74(3):111-5. PubMed ID: 9111423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
    Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
    Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
    Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
    Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML.
    Gandini D; De Angeli C; Aguiari G; Manzati E; Lanza F; Pandolfi PP; Cuneo A; Castoldi GL; del Senno L
    Leukemia; 2002 May; 16(5):886-93. PubMed ID: 11986951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vitamin K2 therapy for myelodysplastic syndrome].
    Abe Y; Muta K; Hirase N; Choi I; Matsushima T; Hara K; Taguchi F; Suematsu E; Shibata K; Uike N; Nishimura J; Nawata H
    Rinsho Ketsueki; 2002 Feb; 43(2):117-21. PubMed ID: 11925874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
    Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM; de Witte T; de Pauw BE; Haanen C
    Neth J Med; 1990 Feb; 36(1-2):19-24. PubMed ID: 2314517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.